Centocor Exiting Diagnostics Business To Focus Exclusively on Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Centocor's commitment to its core pharmaceutical operation has been reinforced by the company's Oct. 30 announcement that it will sell its oncology diagnostics business to the Japanese firm Fujirebio for $37.5 mil.